Legend Biotech CEO Ying Huang

#AS­CO22: Leg­end, J&J say Carvyk­ti holds up past the two-year mark as pair preps for po­ten­tial sec­ond nod

CHICA­GO — The sec­ond BC­MA CAR-T ap­proved, Carvyk­ti, has shown it can stay ef­fec­tive at al­most 28 months of me­di­an fol­low-up, with over­all re­sponse rate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA